Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARα axis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZDZhenfeng DaiQSQiqi ShenJZJianbiao Zhou

Discussion

Loading...

Member takes

Overview

Functional validation reveals super-enhancer driven TRIM47 regulation enhances immunotherapy efficacy in multiple myeloma.

Key Points

  • The study investigates the MAF-TRIM47-RARα axis's role in regulating CD38 expression in multiple myeloma.
  • Analyzed MAF transcription factor's effect on TRIM47 expression using MAF knockdown in MM cell lines.
  • Performed ChIP-seq and ATAC-seq to study MAF binding and super-enhancer activity.
  • Utilized ubiquitinomics and proteomics screens to identify TRIM47 interacting partners.
  • Conducted in vitro and in vivo experiments to evaluate ATRA's role in enhancing CD38-targeted immunotherapy.
  • Knockdown of MAF significantly reduced TRIM47 levels in MM cell lines.
  • TRIM47 ablation enhanced CD38 expression and response to ATRA treatment.
  • Co-culture studies with TRIM47 knockdown myeloma cells improved CAR-T-mediated killing.
  • In vivo models showed TRIM47 targeting combined with ATRA led to tumor regression.

Cite This Study

Dai et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db6ehttps://doi.org/10.1182/blood-2025-2156
View Full Paper
Ask AI
Bookmark
Share